Albert David Limited
NSE: ALBERTDAVD
NSE
748.80
-1.50 (-0.20%)
Prev Close
750.3
Open Price
750.8
Volume
1,419
Today Low / High
746.05 / 759
52 WK Low / High
736.05 / 1400
Range
711 - 786
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 748.8, with a change of -1.5 (-0.19992%). The expected target range on the NSE is between 711 - 786. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
24 Dec
750.80
-0.27%
23 Dec
751.70
-0.19%
22 Dec
749.50
0.22%
19 Dec
747.20
-0.49%
18 Dec
745.05
0.20%
17 Dec
747.70
0.05%
16 Dec
752.05
-0.92%
15 Dec
770.05
-2.34%
12 Dec
779.80
-1.22%
11 Dec
756.30
1.63%
10 Dec
769.95
-2.48%
09 Dec
751.80
1.04%
08 Dec
779.65
-3.09%
05 Dec
775.00
1.10%
04 Dec
786.00
-1.77%
03 Dec
786.65
-0.90%
02 Dec
788.90
0.25%
01 Dec
790.00
-0.75%
28 Nov
800.00
-0.89%
27 Nov
798.00
-0.83%
Albert David Limited Graph
Albert David Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Albert David Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 748.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 748.80 | 756.29 | 680.66 - 831.92 |
| 763.78 | 611.02 - 916.53 | ||
| 771.26 | 539.88 - 1,002.64 | ||
| Bearish Scenario | 748.80 | 741.31 | 667.18 - 815.44 |
| 733.82 | 587.06 - 880.59 | ||
| 726.34 | 508.44 - 944.24 |
Overview of Albert David Limited
ISIN
INE155C01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
3,044
Market Cap
4,273,522,906
Last Dividend
5
Official Website
IPO Date
2016-06-14
DCF Diff
-702.23
DCF
1,451
Financial Ratios Every Investor Needs
Stock Dividend of ALBERTDAVD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-25 | July 25, 25 | 5 | 5 | 2025-07-25 | 2025-09-01 | |
| 2024-08-02 | August 02, 24 | 11.5 | 11.5 | 2024-08-02 | 2024-09-08 | |
| 2023-08-02 | August 02, 23 | 9 | 9 | 2023-08-03 | 2023-09-09 | |
| 2022-08-01 | August 01, 22 | 9 | 9 | 2022-08-02 | 2022-09-08 | |
| 2021-09-06 | September 06, 21 | 6 | 6 | 2021-09-07 | 2021-10-14 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 345.77 Cr | 116.28 Cr | 229.48 Cr | 0.6637 | 2.89 Cr | 109.42 Cr | 120.46 Cr | 17.20 Cr | 30.14 | 3.03 Cr | 0.0497 |
| 2024-03-31 | 360.26 Cr | 128.40 Cr | 231.86 Cr | 0.6436 | 1.95 Cr | 89.14 Cr | 43.17 Cr | 75.42 Cr | 132.15 | 104.54 Cr | 0.2093 |
| 2023-03-31 | 341.56 Cr | 123.09 Cr | 218.48 Cr | 0.6396 | 1.90 Cr | 49.74 Cr | 39.13 Cr | 36.17 Cr | 63.39 | 59.87 Cr | 0.1059 |
| 2022-03-31 | 312.43 Cr | 117.52 Cr | 194.91 Cr | 0.6239 | 1.60 Cr | 35.56 Cr | 34.49 Cr | 35.26 Cr | 61.78 | 56.78 Cr | 0.1129 |
| 2021-03-31 | 246.31 Cr | 88.03 Cr | 158.29 Cr | 0.6426 | 1.53 Cr | 28.94 Cr | 12.97 Cr | 22.14 Cr | 38.80 | 36.46 Cr | 0.0899 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.69 Cr | 511.42 Cr | 118.93 Cr | 392.4834 Cr | 12.32 Cr | 10.62 Cr | 63.90 Cr | 99.44 Cr | 0.00 Cr | 0.00 Cr | 56.05 Cr | 104.1800 Cr |
| 2024-03-31 | 5.44 Cr | 497.99 Cr | 115.01 Cr | 382.9810 Cr | 3.32 Cr | -2.11 Cr | 43.61 Cr | 88.28 Cr | 3.24 Cr | 0.00 Cr | 32.84 Cr | 99.0476 Cr |
| 2023-03-31 | 1.45 Cr | 423.39 Cr | 111.83 Cr | 311.5676 Cr | 5.32 Cr | 3.87 Cr | 50.68 Cr | 80.28 Cr | 58.73 Cr | -3.97 Cr | 29.88 Cr | 98.9375 Cr |
| 2022-03-31 | 2.28 Cr | 402.84 Cr | 123.37 Cr | 279.4711 Cr | 5.66 Cr | 3.39 Cr | 39.18 Cr | 84.62 Cr | 1.44 Cr | 0.00 Cr | 55.55 Cr | 107.3331 Cr |
| 2021-03-31 | 5.08 Cr | 341.40 Cr | 97.02 Cr | 244.3820 Cr | 1.62 Cr | -3.46 Cr | 35.75 Cr | 83.24 Cr | 44.63 Cr | 0.00 Cr | 28.86 Cr | 80.6091 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -28.4358 Cr | 23.3013 Cr | 0.1103 Cr | -43.2917 Cr | -5.0216 Cr | 0.4173 Cr | -14.8559 Cr | 17.2008 Cr | 7.9493 Cr | -6.5481 Cr | -20.2899 Cr |
| 2024-03-31 | 45.5022 Cr | -33.2483 Cr | -8.2699 Cr | 34.6282 Cr | 3.9935 Cr | 5.4389 Cr | -10.8740 Cr | 75.4201 Cr | -1.8690 Cr | -5.1691 Cr | 7.0704 Cr |
| 2023-03-31 | 10.5150 Cr | -4.9952 Cr | -6.3622 Cr | 5.2781 Cr | -0.8308 Cr | 1.4454 Cr | -5.2369 Cr | 50.7354 Cr | 0.2032 Cr | -5.1498 Cr | -11.5033 Cr |
| 2022-03-31 | 40.3647 Cr | -39.6973 Cr | -1.2587 Cr | 29.2833 Cr | -4.1323 Cr | -1.4895 Cr | -11.0814 Cr | 47.2976 Cr | 3.3328 Cr | -3.4358 Cr | -3.4311 Cr |
| 2021-03-31 | 36.6107 Cr | -36.6844 Cr | -1.7050 Cr | 34.9786 Cr | -1.7741 Cr | 4.6428 Cr | -1.6321 Cr | 27.4436 Cr | -1.2163 Cr | -0.0402 Cr | 6.9748 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 87.24 Cr | 59.96 Cr | 27.29 Cr | 0.3128 | 0.31 Cr | -3.30 Cr | -5.79 | 0.40 Cr | -0.0378 |
| 2025-06-30 | 70.57 Cr | 25.28 Cr | 45.29 Cr | 0.6418 | -13.04 Cr | 7.94 Cr | 13.91 | 11.38 Cr | 0.1125 |
| 2025-03-31 | 74.89 Cr | 29.33 Cr | 45.57 Cr | 0.6084 | 86.24 Cr | -10.33 Cr | -18.10 | -39.44 Cr | -0.1379 |
| 2024-12-31 | 83.08 Cr | 26.34 Cr | 56.75 Cr | 0.6830 | -1.03 Cr | -9.39 Cr | -16.45 | -8.34 Cr | -0.1130 |
| 2024-09-30 | 98.44 Cr | 30.32 Cr | 68.12 Cr | 0.6920 | 4.55 Cr | 18.07 Cr | 31.67 | 26.86 Cr | 0.1836 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 25.20 Cr | 259.08 Cr | 284.29 Cr | 45.60 Cr | 51.46 Cr | 397.14 Cr | 99.69 Cr | 532.94 Cr | 139.04 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 243.66 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -392.48 Cr |
| 2025-03-31 | 1.69 Cr | 242.21 Cr | 243.91 Cr | 33.71 Cr | 63.90 Cr | 354.05 Cr | 99.44 Cr | 511.42 Cr | 118.93 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 317.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -413.24 Cr |
| 2024-09-30 | 39.52 Cr | 277.50 Cr | 317.02 Cr | 38.66 Cr | 47.48 Cr | 416.15 Cr | 95.32 Cr | 535.33 Cr | 122.10 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 7.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -10.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -9.39 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 18.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 18.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,737.00 | ₹4,167,644,842,890.00 | ₹2,224,444.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,496.50 | ₹1,724,616,629,970.00 | ₹252,785.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,834.30 | ₹1,297,701,350,592.00 | ₹152,697.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,265.80 | ₹1,053,794,354,145.00 | ₹1,265,207.00 |
| Lupin Limited | LUPIN | ₹2,107.00 | ₹962,475,084,242.00 | ₹473,276.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹917.80 | ₹923,521,556,022.00 | ₹745,138.00 |
| Mankind Pharma Limited | MANKIND | ₹2,193.30 | ₹905,405,364,418.00 | ₹269,608.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,211.40 | ₹703,583,086,102.00 | ₹253,875.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,566.00 | ₹665,498,790,000.00 | ₹41,223.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,084.80 | ₹585,636,420,154.00 | ₹1,708,663.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,020.10 | ₹570,073,854,261.00 | ₹579,252.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,414.70 | ₹358,915,357,205.00 | ₹49,571.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,734.50 | ₹341,636,463,828.00 | ₹1,012,434.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,815.50 | ₹284,399,810,618.00 | ₹47,822.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,411.10 | ₹267,494,959,835.00 | ₹253,413.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,437.00 | ₹233,501,246,853.00 | ₹434,153.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,168.00 | ₹229,200,000,000.00 | ₹4,561.00 |
| Eris Lifesciences Limited | ERIS | ₹1,545.00 | ₹210,455,096,595.00 | ₹30,952.00 |
| Cohance Lifesciences Limited | COHANCE | ₹536.20 | ₹205,132,500,468.00 | ₹297,194.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,086.00 | ₹193,551,705,454.00 | ₹64,393.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,066.60 | ₹169,054,430,771.00 | ₹67,188.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹857.20 | ₹168,493,909,893.00 | ₹41,082.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹916.25 | ₹164,109,418,388.00 | ₹309,335.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,970.10 | ₹149,750,642,290.00 | ₹16,243.00 |
| Granules India Limited | GRANULES | ₹612.40 | ₹148,610,321,678.00 | ₹3,335,314.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.65 | ₹110,983,681,468.00 | ₹21,653.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,641.00 | ₹93,637,113,862.00 | ₹2,377.00 |
| Strides Pharma Science Limited | STAR | ₹938.30 | ₹86,485,657,546.00 | ₹168,043.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹759.80 | ₹68,873,813,981.00 | ₹89,640.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.30 | ₹68,329,448,485.00 | ₹179,190.00 |
| FDC Limited | FDC | ₹409.15 | ₹66,613,745,869.00 | ₹37,886.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹318.80 | ₹62,351,482,941.00 | ₹177,808.00 |
| Sequent Scientific Limited | SEQUENT | ₹213.86 | ₹53,427,321,931.00 | ₹430,552.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹437.80 | ₹47,704,993,017.00 | ₹1,374,079.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.61 | ₹44,008,372,549.00 | ₹827,096.00 |
| Innova Captab Limited | INNOVACAP | ₹714.95 | ₹40,912,962,989.00 | ₹16,795.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹772.40 | ₹39,175,436,702.00 | ₹30,197.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,352.30 | ₹38,904,724,985.00 | ₹2,228.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹422.00 | ₹38,515,940,000.00 | ₹417,255.00 |
| Suven Life Sciences Limited | SUVEN | ₹167.61 | ₹36,942,252,174.00 | ₹95,828.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹342.15 | ₹34,311,659,428.00 | ₹18,106.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹448.55 | ₹31,580,499,163.00 | ₹18,057.00 |
| Hikal Limited | HIKAL | ₹238.15 | ₹29,364,073,613.00 | ₹452,521.00 |
Key Executives
Corporate Head of Human Resource
Adi Joyti Chattopadhyay
Gender: male
Year Born: 1962
Head of QA (Contract Manufacturing)
Anil Kumar Semwal
Gender: male
Year Born:
Executive Chairman
Arun Kumar Kothari
Gender: male
Year Born: 1953
Head of Operations - Ghaziabad Plant
Chandra Thakur
Gender: male
Year Born:
Company Secretary, Compliance Officer & Chief Investor Relations Officer
Lalit Lohia
Gender: male
Year Born: 1984
Chief Financial Officer
Ranadeep Bhattacharya
Gender: male
Year Born: 1971
Plant Head - Kolkata
Santanu Bhattacharya
Gender: male
Year Born: 1969
Divisional Head of Sunrise
Santosh Kumar Dubey
Gender: male
Year Born:
Head of Sales Training
Siddhesh Subhash Rege
Gender: male
Year Born:
MD, CEO & Director
Umesh Manohar Kunte
Gender: male
Year Born: 1969
FAQs about Albert David Limited
Who is the CEO of the company?
The CEO is Umesh Manohar Kunte.
What is the current market price of the stock?
The current price is ₹748.80.
What is the 52-week price range?
The range is ₹736.05-1400.
What is the market capitalization of the company?
The market capitalization is ₹427.35 crores.
What is the dividend yield?
The dividend yield is 0.67%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 67.89.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Albert David Limited (ISIN: INE155C01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹427.35 crores and an average daily volume of 3,044 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹5.